Investment firm Cantor Fitzgerald has restated its positive stance on Vaxcyte (NASDAQ:PCVX) by retaining an Overweight rating, based on a research release published on Friday. The infectious disease-focused developer of vaccines commands a market valuation of approximately $7.05 billion, with its shares appreciating by 47.6% over the last six months. This price increase comes despite the stock still being priced below InvestingPro’s determined Fair Value benchmark.
The sustained bullish outlook from Cantor Fitzgerald is reinforced by Vaxcyte’s steady advancement of its vaccine candidates through the clinical trial process. Notably, the company reported a diluted earnings per share of negative $4.84 over the trailing twelve months, confirming continued unprofitability at this stage.
Within its report, Cantor Fitzgerald detailed expectations for a topline readout from the Phase 3 OPUS-1 trial by the fourth quarter of 2026. This study is being conducted as a non-inferiority assessment of Vaxcyte’s product, with plans to file a Biologics License Application (BLA) for adult use targeted for 2027.
Moreover, the OPUS-2 Phase 3 trial has commenced with the enrollment of its first participant, while the OPUS-3 trial is slated to start in early 2026. Both these late-stage trials are anticipated to provide results during the first half of 2027, marking critical milestones in Vaxcyte's pipeline progression.
The company’s infant vaccine program, specifically the Phase 2 VAX-31 trial, remains on schedule with projected primary and booster outcome data expected by mid-2027.
Additional recent developments include the initiation of the Phase 3 OPUS trial for the VAX-31 pneumococcal conjugate vaccine, which is enrolling about 4,000 participants. This trial is designed to compare the investigational vaccine directly with established vaccines Capvaxive and Prevnar 20.
Analyst support remains robust beyond Cantor Fitzgerald’s evaluation. Jefferies has upheld a Buy rating, citing the trial’s adherence to planned timelines and rigorous statistical protocols. Leerink Partners raised its price target for Vaxcyte from $60 to $77 following encouraging feedback from a recent non-deal roadshow. Evercore ISI continues to maintain an Outperform rating, noting favorable changes to CDC vaccination guidance which could enhance market potential.
These industry perspectives collectively underscore a strong degree of confidence in Vaxcyte’s vaccine candidate portfolio and the methodical progress across its clinical programs.